Overview

Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate safety and tolerability to estimate the maximum tolerated dose and/or recommended dose of oral LCL161 in Japanese patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel